Adjuvant Deal with CSL
Opsona Raises €18M for Anti-TLR-2 Antibody
No Abstract
BioWorld Today Correspondent
DUBLIN, Ireland - Opsona Therapeutics Ltd. raised €18 million (US$23 million) in a Series B round and unveiled a research and collaboration agreement with CSL Ltd., based on the identification of novel vaccine adjuvant formulations using its proprietary OpsoVac immunotherapy platform.